Morningstar

Telix Pharmaceuticals Ltd Ordinary Shares TLX

Morningstar Rating
Unlock
Stock XASX Rating as of
A$20.73 +0.29 (1.42%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Telix Pharmaceuticals Earnings: Expenses Tick Up but Long-Term Outlook Intact

Shane Ponraj

No-moat Telix Pharmaceuticals reported interim 2024 underlying EBITDA growth of 66% to AUD 58 million, below our expectations. While group revenue grew strongly by 29% on second half 2023, underlying operating expenditure, excluding research and development, grew by 35%. Higher expenses were driven by increased investment in salesforce operations and unexpectedly high investment in infrastructure to support commercial operations.

Read Full Report

Price vs Fair Value

View History
TLX is trading at a 220% premium.
Price
A$20.73
Fair Value
A$12.00
Uncertainty
High
1-Star Price
A$17.42
5-Star Price
A$76.50
Economic Moat
Kyllr
Capital Allocation
Kgkfzdlgx

Bulls Say, Bears Say

Bulls

Illuccix has gained significant market share due to changes in clinical practice and successful distribution.

Bears

There is high uncertainty on the continued success of Illuccix and timing and adoption of its product pipeline.

Show More

News

View All

Trading Information

Previous Close Price
A$20.44
Day Range
A$20.16–20.73
52-Week Range
A$8.20–21.00
Bid/Ask
A$20.49 / A$20.75
Market Cap
A$6.94 Bil
Volume/Avg
1.0 Mil / 1.7 Mil

Key Statistics

Price/Earnings (Normalized)
68.16
Price/Sales
10.64
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield
—

Company Profile

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Growth
Total Number of Employees
—
Website
https://www.telixpharma.com

Competitors

Valuation

View More
Metric
TLX
NVS
CUV
Price/Earnings (Normalized)
 68.1616.4217.01
Price/Book Value
 17.155.613.46
Price/Sales
 10.644.888.12
Price/Cash Flow
 136.3814.9619.32
Price/Earnings
TLX
NVS
CUV

Financial Strength

Metric
TLX
NVS
CUV
Quick Ratio
 0.810.612.44
Current Ratio
 0.990.938.81
Interest Coverage
 3.9512.3410.73
Quick Ratio
TLX
NVS
CUV

Profitability

Metric
TLX
NVS
CUV
Return on Assets (Normalized)
 14.10%13.97%19.84%
Return on Equity (Normalized)
 32.61%33.01%23.11%
Return on Invested Capital (Normalized)
 36.31%20.66%21.89%
Return on Assets
TLX
NVS
CUV

Biotechnology Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk AS ADR
NVO
VnhwzxjvSmfql$531.4 Bil
 Vertex Pharmaceuticals Inc
VRTX
LmkxlzxbdXxkxw$119.5 Bil
 Regeneron Pharmaceuticals Inc
REGN
NxzrvtvqLbgkjk$114.9 Bil
 Alnylam Pharmaceuticals Inc
ALNY
GnjvvcxDxgnk$35.3 Bil
 argenx SE ADR
ARGX
QgvnczrMsh$32.0 Bil
 BioNTech SE ADR
BNTX
JyhtzcfflQkmm$28.1 Bil
 Moderna Inc
MRNA
PwwbnrlcQsrv$25.3 Bil
 United Therapeutics Corp
UTHR
BbpzrpnsBtcky$16.0 Bil
 Biomarin Pharmaceutical Inc
BMRN
YcbckkvzHrcncn$13.4 Bil
 Incyte Corp
INCY
MjnmdlbKwdwbbr$12.7 Bil

Sponsor Center